A patient advocating for transparent science in rare disease research
Abstract 300 million people live with at least one of 6,000 rare diseases worldwide. However, rare disease research is not always reviewed with scrutiny, making it susceptible to what the author refers to as nontransparent science. Nontransparent science can obscure animal model flaws, misguide medi...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-01-01
|
| Series: | Orphanet Journal of Rare Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13023-022-02557-6 |
| _version_ | 1797945751326687232 |
|---|---|
| author | Richard Rui Yang |
| author_facet | Richard Rui Yang |
| author_sort | Richard Rui Yang |
| collection | DOAJ |
| description | Abstract 300 million people live with at least one of 6,000 rare diseases worldwide. However, rare disease research is not always reviewed with scrutiny, making it susceptible to what the author refers to as nontransparent science. Nontransparent science can obscure animal model flaws, misguide medicine regulators and drug developers, delay or frustrate orphan drug development, or waste limited resources for rare disease research. Flawed animal models not only lack pharmacologic relevance, but also give rise to issue of clinical translatability. Sadly, these consequences and risks are grossly overlooked. Nontransparency in science can take many forms, such as premature publication of animal models without clinically significant data, not providing corrections when flaws to the model are discovered, lack of warning of critical study limitations, missing critical control data, questionable data quality, surprising results without a sound explanation, failure to rule out potential factors which may affect study conclusions, lack of sufficient detail for others to replicate the study, dubious authorship and study accountability. Science has no boarders, neither does nontransparent science. Nontransparent science can happen irrespective of the researcher’s senority, institutional affiliation or country. As a patient-turned researcher suffering from Bietti crystalline dystrophy (BCD), I use BCD as an example to analyze various forms of nontransparent science in rare disease research. This article analyzes three papers published by different research groups on Cyp4v3 −/−, high-fat diet (HFD)-Cyp4v3 −/−, and Exon1-Cyp4v3 −/− mouse models of BCD. As the discussion probes various forms of nontransparent science, the flaws of these knockout mouse models are uncovered. These mouse models do not mimic BCD in humans nor do they address the lack of Cyp4v3 (murine ortholog of human CYP4V2) expression in wild type (WT) mouse retina which is markedly different from CYP4V2 expression in human retina. Further, this article discusses the impact of nontransparent science on drug development which can lead to significant delays ultimately affecting the patients. Lessons from BCD research can be helpful to all those suffering from rare diseases. As a patient, I call for transparent science in rare disease research. |
| first_indexed | 2024-04-10T21:00:05Z |
| format | Article |
| id | doaj.art-935b9828060c495fb814c48831572a18 |
| institution | Directory Open Access Journal |
| issn | 1750-1172 |
| language | English |
| last_indexed | 2024-04-10T21:00:05Z |
| publishDate | 2023-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Orphanet Journal of Rare Diseases |
| spelling | doaj.art-935b9828060c495fb814c48831572a182023-01-22T12:24:58ZengBMCOrphanet Journal of Rare Diseases1750-11722023-01-0118111910.1186/s13023-022-02557-6A patient advocating for transparent science in rare disease researchRichard Rui Yang0Reflection Biotechnologies LimitedAbstract 300 million people live with at least one of 6,000 rare diseases worldwide. However, rare disease research is not always reviewed with scrutiny, making it susceptible to what the author refers to as nontransparent science. Nontransparent science can obscure animal model flaws, misguide medicine regulators and drug developers, delay or frustrate orphan drug development, or waste limited resources for rare disease research. Flawed animal models not only lack pharmacologic relevance, but also give rise to issue of clinical translatability. Sadly, these consequences and risks are grossly overlooked. Nontransparency in science can take many forms, such as premature publication of animal models without clinically significant data, not providing corrections when flaws to the model are discovered, lack of warning of critical study limitations, missing critical control data, questionable data quality, surprising results without a sound explanation, failure to rule out potential factors which may affect study conclusions, lack of sufficient detail for others to replicate the study, dubious authorship and study accountability. Science has no boarders, neither does nontransparent science. Nontransparent science can happen irrespective of the researcher’s senority, institutional affiliation or country. As a patient-turned researcher suffering from Bietti crystalline dystrophy (BCD), I use BCD as an example to analyze various forms of nontransparent science in rare disease research. This article analyzes three papers published by different research groups on Cyp4v3 −/−, high-fat diet (HFD)-Cyp4v3 −/−, and Exon1-Cyp4v3 −/− mouse models of BCD. As the discussion probes various forms of nontransparent science, the flaws of these knockout mouse models are uncovered. These mouse models do not mimic BCD in humans nor do they address the lack of Cyp4v3 (murine ortholog of human CYP4V2) expression in wild type (WT) mouse retina which is markedly different from CYP4V2 expression in human retina. Further, this article discusses the impact of nontransparent science on drug development which can lead to significant delays ultimately affecting the patients. Lessons from BCD research can be helpful to all those suffering from rare diseases. As a patient, I call for transparent science in rare disease research.https://doi.org/10.1186/s13023-022-02557-6Patient perspectiveTransparent scienceRare Disease ResearchOrphan Drug DevelopmentCyp4v3 knockout mouseBietti Crystalline Dystrophy |
| spellingShingle | Richard Rui Yang A patient advocating for transparent science in rare disease research Orphanet Journal of Rare Diseases Patient perspective Transparent science Rare Disease Research Orphan Drug Development Cyp4v3 knockout mouse Bietti Crystalline Dystrophy |
| title | A patient advocating for transparent science in rare disease research |
| title_full | A patient advocating for transparent science in rare disease research |
| title_fullStr | A patient advocating for transparent science in rare disease research |
| title_full_unstemmed | A patient advocating for transparent science in rare disease research |
| title_short | A patient advocating for transparent science in rare disease research |
| title_sort | patient advocating for transparent science in rare disease research |
| topic | Patient perspective Transparent science Rare Disease Research Orphan Drug Development Cyp4v3 knockout mouse Bietti Crystalline Dystrophy |
| url | https://doi.org/10.1186/s13023-022-02557-6 |
| work_keys_str_mv | AT richardruiyang apatientadvocatingfortransparentscienceinrarediseaseresearch AT richardruiyang patientadvocatingfortransparentscienceinrarediseaseresearch |